Navigation Links
Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team
Date:12/18/2013

SOUTH PLAINFIELD, N.J., Dec. 18, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality, today announced the addition of Ronald G. Jubin, Ph.D. to their executive team as Managing Director, Research and Development. In his new role, Dr. Jubin will be responsible for pre-clinical discovery, methods development and the advancement of Prolong's pipeline candidates.

(Logo:  http://photos.prnewswire.com/prnh/20130926/NY87531LOGO )

"Ron brings more than two decades of experience at the forefront of drug discovery to our efforts here at Prolong," said Dr. Abraham Abuchowski, Prolong's Chief Scientific Officer and CEO. "We are excited to bring him on board at this important time in our company history." In October, Prolong presented Phase I data for its flagship product SANGUINATE an intravenous therapeutic that combines the beneficial functions of a carbon monoxide releasing molecule with an oxygen transfer agent as well as acting as a plasma expander. SANGUINATE was found to be well tolerated with no serious adverse events, and is now moving forward into Phase II trials in patients with sickle cell disease who suffer from painful vaso-occlusive crises. 

Dr. Jubin's experience includes key roles at Schering-Plough Research Institute and PBL Biomedical labs. At Schering-Plough, he served in major roles in the hepatitis C protease program, directed other HCV inhibitor programs and managed internal committees evaluating novel interferon candidate licensing opportunities. At PBL Biomedical, his tenure leading the R&D department at PBL resulted in the development of numerous interferon proteins, reagents and functional assay for evaluating immune and interferon functions.  Dr. Jubin received his Ph.D. in Microbiology and Molecular Genetics from the UMDNJ-NJMS Graduate School of Biomedical Sciences, Newark, NJ.

"This is an opportunity to work with the inventors of the world's leading drug delivery technology, PEGYLATION, at its birthplace here in New Jersey," said Dr. Jubin. "This is the sort of environment where historic, groundbreaking drug developments occur, and I am looking forward to being a part of the leadership team." 

About Sanguinate

SANGUINATE is an investigational biopharmaceutical product that has a multiple mechanisms of action designed to release therapeutic carbon monoxide and actively transfer oxygen to hypoxic tissue. SANGUINATE has completed Phase I safety trials and is beginning trials in SCD patients.

About Prolong Pharmaceuticals 

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical cost and significant mortality. The company's lead product, SANGUINATE™, is in clinical testing, focused on treating the comorbidities of sickle cell disease and other disorders where oxygen deprivation due to hemolysis and/or ischemia occurs.  The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. For more information visit: www.prolongpharma.com.


'/>"/>
SOURCE Prolong Pharmaceuticals LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
2. Prolong TM, a New Revolutionary First Line Treatment for Premature Ejaculation is Licensed in Europe
3. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):